Dr Rob Schott Joins Nutcracker Therapeutics as CMO

Biotechnology company Nutcracker Therapeutics has appointed Rob Schott, M.D., M.P.H, F.A.C.C., as Chief Medical Officer.

The California-based company develops RNA therapies through its proprietary technology platform, NTX-0250.

Dr Schott will guide the clinical advancement of the company’s oncology pipeline.

Igor Khandros, Ph.D., cofounder and Chief Executive Officer of Nutcracker Therapeutics, said:

“Rob’s extensive background, which includes driving successful clinical development programs within the pharmaceutical and biotechnology industries, gives us full confidence in his ability to oversee the continuous evolution of our pipeline.

“The biological versatility of RNA equips Nutcracker Therapeutics with the tools to reimagine the treatment landscape of oncology, and beyond.

“Dr Schott’s robust track record adds a new dimension of invaluable industry know-how to a team of talented individuals working to bring transformative RNA therapies to patients.”

Dr Schott joins Nutcracker Therapeutics from Sangamo Therapeutics, where, as Senior Vice President and Head of Development, he spearheaded clinical strategy across numerous programmes.

Dr Schott previously served as Chief Medical Officer at Chorus – an operationally independent subsidiary of Eli Lilly and Company

There, he led the implementation of innovative processes designed to achieve clinical proof-of-concept more efficiently for early-stage drug candidates.

Dr Schott said:

“I see RNA as a drug modality with enormous potential, so I immediately connected with Nutcracker Therapeutics’ distinct methodology of RNA drug development.

“The unique ability of the company’s technology platform to rapidly design and interrogate RNA molecules will be key to realising the therapeutic potential of this drug class within oncology and beyond.

“I look to utilise my clinical expertise to advance Nutcracker Therapeutics’ pipeline and contribute to a culture built on dedication to improving patient lives.”